Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...

Recommended Reading Pfizer marks progress for successor sickle cell drug at ASH Pfizer is pulling the sickle cell disease drug Oxbryta off the market and ending clinical trials of the medicine ...

Pfizer’s startling announcement late Wednesday that it would pull its pill for sickle-cell disease off pharmacy shelves is a blow to the drugmaker’s efforts to buy its way through an impending ...

Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. See why I think that 2025 will not be a strong year for PFE stock.

If you've experienced serious side effects from Oxbryta, find out if you qualify for compensation. CHEYENNE, WY / ACCESSWIRE / October 23, 2024 / InjuryClaims.com is connecting people who may have ...